

SYNTHESIS AND ANTIMICROBIAL EVALUATION OF 2-(5-(SUBSTITUTED PHENYL-1H-TETRAZOL-1-YL) PYRIDINES

SHINY GEORGE^a AND P. SHANMUGAPANDIYAN^{b*}^aDepartment of Pharmaceutical Chemistry, Karpagam University, Coimbatore-21, ^bMohamed Sathak A.J College of Pharmacy, Sholinganallur, Chennai- 600 119, India. Email: shanmugapandiyan@gmail.com

Received: 20 Oct 2011, Revised and Accepted: 25 Sep 2011

ABSTRACT

A new series of 2-(5-substituted phenyl-1H-tetrazol-1-yl) pyridine has been synthesized by the [3+2] cycloaddition of N-pyridyl-2-yl imidoformylchloride-benzene and sodium azide. The chemical structure of the synthesized compounds was confirmed by means of IR, ¹H NMR and Mass spectral analysis. All the synthesized compounds were screened for their antibacterial (*Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli* and *Pseudomonas aeruginosa*) and antifungal activities (*Aspergillus fumigatus* and *Candida albicans*) by cup plate method. All the synthesized compounds have exhibited significant activity against the bacteria and fungi tested. Compounds 2-(5-(4-chlorophenyl)-1H-tetrazol-1-yl) pyridine and 2-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)pyridine were having a very good antibacterial activity against *Pseudomonas aeruginosa* and *E.coli*. Compound 2-(5-(3-bromophenyl)-1H-tetrazol-1-yl)pyridine having a very good antibacterial activity against *Bacillus subtilis*.

Keywords: Pyridine, Tetrazole, Antibacterial, Antifungal.

INTRODUCTION

The emergence and spread of antimicrobial resistance has become one of the most serious public health concerns across the world. Tetrazoles are medicinally important heterocycles incorporated in a large number of drugs. Tetrazole, an aromatic azapyrrole group, is metabolically stable and has acidic characteristics closely similar to that of the carboxylic group¹. Tetrazole and its derivatives possessing a wide spectrum of biological activities including antibacterial^{2,3}, antifungal and anticonvulsant⁴, analgesic⁵, anti-inflammatory⁶, antitubercular activity⁷, anticancer activity⁸ and anti-hypertensive⁹ activities. 1, 5 disubstituted tetrazoles have long been known for their pharmaceutical activity as stimulants or depressants on the central nervous system and are reported to show oral antidiabetic and antithrombotic and antimicrobial properties¹⁰. In addition pyridines are associated with diverse biological activities. Inspired by the biological profile of tetrazole and pyridine on biologically active heterocycles it was thought worthwhile to synthesize new chemical entities with two active pharmacophores in a single molecular framework in order to prepare molecules having potentially enhanced biological activities. In the present study synthesis of a new series of 2-(5-phenyl-1H-tetrazol-1-yl)pyridine and their antibacterial (*Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli* and *Pseudomonas aeruginosa*) and antifungal activities (*Aspergillus fumigatus* and *Candida albicans*) by cup plate method.

MATERIALS AND METHOD

Melting points were determined in open capillaries and were uncorrected. The purity of the synthesized compounds was routinely checked by TLC on silica gel G. ¹H and ¹³C NMR spectra was recorded on JEOL GSX 400 spectrometer using TMS as an internal standard (chemical shifts in δ , ppm), IR spectra on a Perkin Elmer 1600 FT spectrometer (ν_{\max} cm⁻¹) and Mass spectra on a JEOL MSMATE spectrometer. Microanalysis for C, H and N were performed in a Heraeus CHN Rapid Analyser. The physical data of the title compounds are given in Table 1.

General procedure:

Synthesis of 2- arylaminopyridines (3a-j)

To a solution of 2-aminopyridine (**1**) was added an equimolar amount of aryl chloride (**2a-j**) with constant shaking. After the addition was complete the reaction mixture was allowed to stand at room temperature for 2 hrs. The crude products that separated out on dilution was filtered and recrystallised from ethanol.

Synthesis of N-Pyridyl-2-yl imidoformylchloride-benzene (4a-j)

A mixture of (**3a-j**) (0.004 mol) and PCl₅ (0.004 mol) was heated at 100°C for 1 hr. When the evolution of fumes of HCl was ceased excess of POCl₃ was removed under reduced pressure.

Synthesis of 2-(5-(substituted phenyl-1H-tetrazol-1-yl) pyridine (5a-j)

The residual imidoformyl chloride was treated with an ice cold solution of sodium azide (0.0075 mol) and excess of sodium acetate in water (25 ml) and acetone (30 ml) with stirring. Stirring was continued overnight, acetone was removed under reduced pressure, remaining aqueous portion was extracted with chloroform and dried.

2-(5-phenyl-1H-tetrazol-1-yl)pyridine (5a): IR (KBr): 1590 (C=N), 1156 (Tetrazole) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.22-7.48 (m, 5H, Ar-H), 7.4-8.6 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 122.2, 123.9, 127.5, 128.8, 129.3, 130.7, 136.0, 140.4, 149.1; MS (relative intensity): m/z value 223.09 (M+1); Anal. Calcd. for C₁₂H₉N₅ % C 64.56, H 4.06, N 31.37; found C 64.54, H 4.05, N 31.35

2-(5-(4-nitrophenyl-1H-tetrazol-1-yl)pyridine (5b): IR (KBr): 1598 (C=N), 1525 (NO₂), 1159 (Tetrazole) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.74-7.82 (m, 4H, Ar-H), 7.41-8.62 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 121.6, 123.9, 128.4, 136.0, 136.8, 140.4, 148.4, 149.1; MS (relative intensity): m/z value 268.07 (M+1); Anal. Calcd. for C₁₂H₈N₆O₂ % C 53.73, H 3.01, N 31.33; found C 53.71, H 3.01, N 31.30

2-(5-(2-chlorophenyl)-1H-tetrazol-1-yl)pyridine (5c): IR (KBr): 1620 (C=N), 1153 (Tetrazole), 756 (C-Cl) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.16-7.42 (m, 4H, Ar-H), 7.41-8.62 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 122.2, 123.9, 127.4, 128.9, 129.4, 130.2, 132.3, 136.0, 138.5, 140.4, 149.1; MS (relative intensity): m/z value 257.05 (M+1); Anal. Calcd. for C₁₂H₈ClN₅ % C 55.93, H 3.13, N 27.18; found C 55.90, H 3.13, N 27.16

2-(5-(4-chlorophenyl)-1H-tetrazol-1-yl)pyridine (5d): IR (KBr): 1608 (C=N), 1151 (Tetrazole), 750 (C-Cl) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.33-7.42 (m, 4H, Ar-H), 7.41-8.63 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 122.2, 123.9, 128.8, 128.9, 129.4, 134.3, 136.0, 140.4, 149.1; MS (relative intensity): m/z value 257.05 (M+1); Anal. Calcd. for C₁₂H₈ClN₅ % C 55.93, H 3.13, N 27.18; found C 55.92, H 3.10, N 27.17

2-(5-(4-methoxyphenyl)-1H-tetrazol-1-yl)pyridine (5e): IR (KBr): 1603 (C=N), 1165 (OCH₃), 1154 (Tetrazole) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 6.83-7.37 (m, 4H, Ar-H), 7.41-8.62 (d, 4H, pyridine), 3.73 (s, 3H, OCH₃); ¹³C-NMR (DMSO-*d*₆): δ 55.9, 114.8, 122.2, 123.0,

123.9, 128.5, 136.0, 140.4, 149.1, 160.7; MS (relative intensity): m/z value 253.10 (M+1); Anal. Calcd. for C₁₃H₁₁N₅O % C 61.65, H 4.38, N 27.65; found C 61.63, H 4.37, N 27.63

2-(5-p-tolyl-1H-tetrazol-1-yl)pyridine (5f): IR (KBr): 1593 (C=N), 1155 (Tetrazole) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.12-7.36 (m, 4H, Ar-H), 7.42-8.63 (d, 4H, pyridine), 2.35 (s, 3H, CH₃); ¹³C-NMR (DMSO-*d*₆): δ 24.3, 122.2, 123.9, 127.4, 127.7, 129.6, 136.0, 138.4, 140.4, 149.1; MS (relative intensity): m/z value 237.1 (M+1); Anal. Calcd. for C₁₃H₁₁N₅ % C 65.81, H 4.67, N 29.52; found C 65.79, H 4.65, N 29.51

2-(5-(3-bromophenyl)-1H-tetrazol-1-yl)pyridine (5g): IR (KBr): 1609 (C=N), 1157 (Tetrazole), 570 (C-Br) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.21-7.65 (m, 4H, Ar-H), 7.42-8.63 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 122.2, 123.6, 123.9, 126.5, 131.5, 131.7, 132.9, 133.1, 136.0, 140.4, 149.1; MS (relative intensity): m/z value 301.00 (M+1); Anal. Calcd. for C₁₂H₈BrN₅ % C 47.70, H 2.67, N 23.18; found C 47.69, H 2.65, N 23.17

2-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)pyridine (5h): IR (KBr): 1619 (C=N), 1158 (Tetrazole), 770 (C-Cl) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 7.14-7.30 (m, 3H, Ar-H), 7.42-8.60 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 122.2, 123.9, 128.2, 132.5, 136.0, 140.4, 149.1, 149.8; MS (relative intensity): m/z value 291.01 (M+1); Anal. Calcd. for C₁₂H₇Cl₂N₅ % C 49.34, H 2.42, N 23.97; found C 49.33, H 2.41, N 23.95

2-(5-(3,5-dinitrophenyl)-1H-tetrazol-1-yl)pyridine (5i): IR (KBr): 1599 (C=N), 1528 (NO₂), 1154 (Tetrazole) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 8.80-9.08 (d, 3H, Ar-H), 7.41-8.64 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 118.7, 122.2, 123.9, 128.2, 132.5, 136.0, 140.4, 149.1, 149.8; MS (relative intensity): m/z value 313.06 (M+1); Anal. Calcd. for C₁₂H₇N₇O₄ % C 46.01, H 2.25, N 31.30; found C 46.02, H 2.23, N 31.32

2-(5-benzyl-1H-tetrazol-1-yl)pyridine (5j): IR (KBr): 1593 (C=N), 1155 (Tetrazole) cm⁻¹; ¹H-NMR (DMSO-*d*₆): δ 3.81 (s, 2H, CH₂), 7.06-7.14 (d, 5H, Ar-H), 7.41-8.61 (d, 4H, pyridine); ¹³C-NMR (DMSO-*d*₆): δ 29.4, 122.2, 123.9, 125.8, 128.7, 129.1, 136.0, 136.3, 140.4, 149.1, 154.5; MS (relative intensity): m/z value 237.1 (M+1); Anal. Calcd. for C₁₃H₁₁N₅ % C 65.81, H 4.67, N 29.52; found C 65.80, H 4.65, N 29.50

Antibacterial activity

The tetrazole derivatives (**5a-j**) were investigated for their inhibition of growth against *Staphylococcus aureus* (ATCC-25923), *Escherichia coli* (ATCC-25922), *Pseudomonas aeruginosa* (ATCC-27853) and *Bacillus subtilis* bacterial strains by the cup plate method^{11, 12}. The test organisms were adjusted to 0.5 McFarland standard. Then by using sterile cotton swab 0.1 ml of suspension is spreaded on to the agar plate and then the plates were allowed to dry for 30 min at room temperature. Then by using sterile agar borer of 6mm diameter the cavities were made on the agar plates and the test drug (50µg/mL) and standard Amoxycillin (30µg/mL) were incorporated into the well and then the plates were kept in a refrigerator for one hour for a period of pre incubation diffusion.

The plates were made in triplicate. Solvent and growth controls were made separately. Then the plates were incubated at 37°C for 24 hours. After incubation zone of inhibition were recorded and tabulate in Table.2.


Antifungal activity

The newly synthesized compounds were also investigated for their antifungal activity¹³ against two fungal strains, namely *Aspergillus fumigatus* (NCIM No.902) and *Candida albicans* (NCCS 3471). Sabouraud agar media was prepared by dissolving peptone (1 g), D-glucose (4 g) and agar (2 g) in sterile water (100 mL) and the pH was adjusted to 5.7. Normal saline was used to make a suspension of the spores of the fungal strain for seeding. The fungal spores were adjusted to a turbidity of 0.5 McFarland standard. Agar media (20 mL) was poured into each petri dish. Then by using sterile cotton swab 0.1 ml of suspension is spreaded on to the agar plate and then the plates were allowed to dry for 30 min at room temperature. Then by using sterile agar borer of 6mm diameter the cavities were made on the agar plates and the test drug (50µg/mL) and standard Ketoconazole (10µg/mL) were incorporated into the well and then the plates were kept in a refrigerator for one hour for a period of pre incubation diffusion. Controls plates were prepared using DMSO at the same concentration as used with the test compounds. The petri dishes were prepared in triplicate and maintained at 28 °C for 3 to 4 days. The antifungal activity was determined by measuring the diameter of the inhibition zone. The results of antifungal studies are given in Table 2.

RESULTS AND DISCUSSION

The synthetic strategy developed to obtain the target compound 2-(5-substituted phenyl-1H-tetrazol-1-yl)pyridine was prepared by the reaction between aminopyridine and aroylchloride with shaking which undergoes nucleophilic addition to give an intermediate N-pyridyl-2-yl-formamide-benzene (**3a-j**) in 80% yield. This on reaction with phosphorous pentachloride under reflux for 1h which undergoes halogenation to give N-pyridyl-2-yl imidoformylchloride benzene (**4a-j**) in 70% yield. Further reaction with sodium azide results in title compounds (**5a-j**) in 52-79% yield. The structures of all the newly synthesized compounds were confirmed by their elemental analysis, IR, ¹H and ¹³C NMR and Mass spectral studies. All the newly synthesized compounds exhibited satisfactory spectral data consistent with their molecular structures.

The synthesized compounds were evaluated for their antimicrobial activity. The antibacterial activity of title compounds revealed that 2-(5-(4-chlorophenyl)-1H-tetrazol-1-yl)pyridine (**5d**), 2-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)pyridine (**5h**) and 2-(5-(3-bromophenyl)-1H-tetrazol-1-yl)pyridine (**5g**) exhibited highest activity against *B.subtilis*, *S. aureus*, *E. coli* and *P. aeruginosa*. Compound 2-(5-(2-chlorophenyl)-1H-tetrazol-1-yl)pyridine (**5c**) having good antifungal effect against *A. fumigatus*



Scheme-1

Table 1: Physical Data of Synthesized Compounds

S. No.	Cpd code	Mol. Formula	m.p ^o C	Yield in %	R _f value
1	5a	C ₁₂ H ₉ N ₅	108	61	0.66
2	5b	C ₁₂ H ₈ N ₆ O ₂	156	52	0.50
3	5c	C ₁₂ H ₈ N ₅ Cl	140	75	0.67
4	5d	C ₁₂ H ₈ N ₅ Cl	145	67	0.60
5	5e	C ₁₃ H ₁₁ N ₅ O	118	64	0.49
6	5f	C ₁₃ H ₁₁ N ₅	127	79	0.59
7	5g	C ₁₂ H ₈ N ₅ Br	110	68	0.75
8	5h	C ₁₂ H ₇ N ₅ Cl ₂	160	59	0.63
9	5i	C ₁₂ H ₇ N ₇ O ₄	172	64	0.65
10	5j	C ₁₃ H ₁₁ N ₅	128	76	0.73

Table 2 Antimicrobial Activities of the Compounds 5a-J

S. No.	Compound code	Zone of inhibition (in mm)					
		Antibacterial activity				Antifungal activity	
		<i>P. aeruginosa</i>	<i>E. coli</i>	<i>B. subtilis</i>	<i>S. aureus</i>	<i>A. fumigatus</i>	<i>C. albicans</i>
1	5a	14	16	10	16	12	15
2	5b	16	14	18	18	17	14
3	5c	19	20	15	13	21	16
4	5d	24	21	19	16	13	11
5	5e	20	12	17	14	16	17
6	5f	17	14	18	17	15	12
7	5g	13	12	20	12	18	15
8	5h	23	19	12	14	20	13
9	5i	16	15	14	17	14	14
10	5j	20	17	16	15	19	22
Amoxycillin (30 µg/ml)		28	25	27	26	-	-
Ketoconazole (10µg/ml)		-	-	-	-	23	24

CONCLUSION

In conclusion a new series of substituted aryl tetrazole derivatives 5a-j has been synthesized and evaluated for their anti microbial activities. Most of the new compounds showed appreciable activity. Among them the compounds **5d**, **5h**, **5g** and **5c** were having a very good antimicrobial activity.

ACKNOWLEDGEMENT

The authors are thankful to Vels University for providing research facilities and also thankful to the authorities of IIT Chennai for providing spectral and analytical data of synthesized compounds.

REFERENCES

- Fidgor SK and Von Wittenau MS Metabolism of 5-(3-pyridyl) tetrazole. J Med Chem 1967; 10: 1158- 1159.
- Sherif Rostom AF, Hayam Ashour MA, Heba Abd El Razik A, Abd Fattah El, Nagwa El-Din N Azole antimicrobial pharmacophore-based tetrazoles: Synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents. Bioorg Med Chem 2009; 17: 2410-2422.
- Mulwad VV, Pawar Rupesh B, Chaskar Atul C Synthesis and antibacterial activity of new tetrazole derivatives. J Korean Chem Soc 2008; 52 (3): 249- 256.
- Upadhayaya RS, Jain S, Sinha N, Kishore N, Chandra R, Arora SK Synthesis of novel substituted tetrazoles having antifungal activity. Eur J Med Chem 2004; 39: 579-592.
- Rajasekaran A, Sankar N, Murugesha A, Kalasalingam, Rajagopal A Antibacterial, antifungal and anticonvulsant evaluation of novel newly synthesized 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzo[d][1, 2,3]triazoles. Archives of Pharmacol Research 2006; 29 (7): 535-540.
- Mohite PB, Pandhare RB, Khanage SG, Bhaskar VH Synthesis and anti-inflammatory activity of some 5-phenyl-1-(acyl)-1, 2, 3, 4-tetrazole. Journal of Pharmacy Research 2010; 3(1): 43-46.
- De Souza AO, Pedrosa MT, Alderete JB, Cruz AF, Prado MA, Alves RB et al Cytotoxicity, antitumoral and antimycobacterial activity of tetrazole and oxadiazole derivatives. Pharmazie 2005; 60(5): 396-397.
- Bhaskar VH, Mohite PB Synthesis, characterization and evaluation of anticancer activity of some tetrazole derivatives. Journal of Optoelectronics and Biomedical Materials 2010; 2 (4): 249 - 259.
- Sharma MC, Kohli DV, Smita Sharma Synthesis and biological evaluation of potent antihypertensive activity: 2-[(Substituted-phenylamino)-phenyl-methyl]-1-[2'-(1H-tetrazol-5-yl) biphenyl-3-ylmethyl]-1H-benzoimidazol-5-ylamine derivatives. International Journal of Advances in Pharmaceutical Sciences 2010; 1: 284-298.
- Ashoke Sharon, Ramendra Pratap, Priti Tiwari, Arvind Srivastava, P R Maulik, Vishnu Ji Ram Synthesis and *in vivo* antihyperglycemic activity of 5-(1H-pyrazol-3-yl)methyl-1H-tetrazoles. Bioorganic & Medicinal Chemistry Letters 2005; 15 (8): 2115-2117.
- Deepti Kohli, Riaz Hashim S, Sagar Vishal, Manish Sharma, Ashutosh Kumar Singh Synthesis and antibacterial activity of quinazolinone derivatives. Int J Pharm Pharm Sci 2009; 1(1): 163-169.
- Murugan S, Umadevi P, Kannika Parameswari N, Mani KR Antimicrobial activity of *Syzygium Jambos* against selected human pathogens. Int J Pharm Pharm Sci 2011; 3 (2): 44-47.
- Holla BS, Mahalinga M, Karthikeyan MS, Akberali PM, Shetty NS Synthesis of some novel pyrazolo[3,4-d]pyrimidine derivatives as potential antimicrobial agents. Bioorg Med Chem 2006; 14: 2040-2047.